AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26855107
Drug: Levonorgestrel contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel contraceptive implant (150 mg), initiated immediately
Trial: 26855107
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (3-month delay in implant initiation)
Trial: 26855107
Drug: Levonorgestrel contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel contraceptive implant (150 mg)
Trial: 18336399
Drug: 12 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 cycles of single-agent paclitaxel (175 mg/m(2) over 3 h every 28 days)
Trial: 18336399
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of the same treatment regimen (paclitaxel)
Trial: 18336399
Drug: 12-cycle maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12-cycle maintenance program with baseline CA-125 level <or=10 units/mL
Trial: 16181163
Drug: Haloperidol 1.5
RxNorm normalized name: haloperidol 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol 1.5 mg/d
Trial: 12749512
Drug: Quetiapine (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (combined groups: 150, 300, 600, and 750 mg)
Trial: 12749512
Drug: Haloperidol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (12 mg)
Trial: 1984710
Drug: Alprazolam 0.25
RxNorm normalized name: alprazolam 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam 0.25 mg t.i.d. for 14 days
Trial: 1984710
Drug: Buspirone 5
RxNorm normalized name: busPIRone 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 5 mg t.i.d. for 14 days
Trial: 22984102
Drug: Control/no treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control/no treatment group (CG)
Trial: 20636227
Drug: Red Yeast
RxNorm normalized name: red yeast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Yeast Rice (RYR) - HypoCol, 4 capsules/day
Trial: 14528656
Drug: H1‐receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1‐receptor antagonist (0.1 mg/kg BW dimetindene) plus H2‐receptor antagonist (5 mg/kg BW cimetidine) diluted with 100 ml 0.9% NaCl
Trial: 14528656
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml 0.9% NaCl)
Trial: 14528656
Drug: H1‐receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1‐receptor antagonist plus H2‐receptor antagonist
Trial: 10632409
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection
Trial: 30920646
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to bear treatment-related toxicities
Trial: 27062270
Drug: Varenicline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (2 mg/d)
Trial: 29438157
Drug: Varenicline (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (2 mg/d) + Low-dose Naltrexone (25 mg/d)
Trial: 22546895
Drug: Intravenous buspirone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buspirone (0.3 mg)
Trial: 22546895
Drug: Intravenous buspirone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous buspirone (1.0 mg)
Trial: 21526663
Drug: Lateral position
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lateral position (group L)
Trial: 15821819
Drug: Intravenous dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dalteparin
Trial: 9931171
Drug: 30 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes of brisk walking 5 to 7 times weekly for 12 weeks
Trial: 2175139
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 or 4 mg in an iv bolus 10 min before insulin or smoking)
Trial: 2175139
Drug: Insulin (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.15 IU/kg in an iv bolus)
Trial: 2175139
Drug: Dexamethasone alone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone alone (2 or 4 mg in an iv bolus)
Trial: 7017189
Drug: L-Keflex
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Keflex
Trial: 16673799
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% shampoo, treated once daily for 4 weeks, rinsed off after 15 minutes
Trial: 16673799
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate gel, leave-on formulation
Trial: 16673799
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate shampoo and gel
Trial: 29796596
Drug: Recorded music
RxNorm normalized name: Recorlev
DrugBank: Levoketoconazole (DB05667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recorded music listening (ML)
Trial: 22155457
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 μg)
Trial: 8911981
Drug: Glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5 mg)
Trial: 20082585
Drug: Technosphere inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technosphere inhaled insulin
Trial: 17640310
Drug: Oral valganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valganciclovir (900 mg daily for 21 days, then 900 mg daily for 28 days)
Trial: 17640310
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (5 mg/kg twice daily for 21 days)
Trial: 12409329
Drug: Granulocyte-macrophage colony-stimulating
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 micro g
Trial: 31987116
Drug: Low energy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low energy diet containing 50 g of Kashk (intervention group)
Trial: 30367257
Drug: Calcium hydroxide-based
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide-based intracanal medication (ICM) after 30 days
Trial: 21941411
Drug: DHA 400
RxNorm normalized name: DuetDHA 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA 400 mg/day from 12th week gestation until 4 months postpartum
Trial: 11133605
Drug: Remifentanil infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusions
Trial: 9644229
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg, n=6; 100 mg, n=2; 120 mg, n=1)
Trial: 2757891
Drug: Digoxin (inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (inhibitor of the sodium/potassium pump)
Trial: 2757891
Drug: Dipyridamole (inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (inhibitor of the anion transporter)
Trial: 2757891
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (oral load)
Trial: 23499390
Drug: Enobosarm 1
RxNorm normalized name: enobosarm
DrugBank: Enobosarm (DB12078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enobosarm 1 mg
Trial: 27138015
Drug: Enobosarm 3
RxNorm normalized name: enobosarm
DrugBank: Enobosarm (DB12078)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enobosarm 3 mg
Trial: 19553295
Drug: Lysine plus
RxNorm normalized name: Lysine Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysine plus glucose (25 g glucose)
Trial: 15987985
Drug: Gamma brachytherapy
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma brachytherapy with an iridium 192 source (14-Gy dose at 2 mm into the arterial wall)
Trial: 12583947
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (n-3 PUFAs)
Trial: 12583947
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil capsules (n-6 PUFAs)
Trial: 1609951
Drug: Midazolam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.25 mg/kg
Trial: 2110954
Drug: Midazolam 0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.35 mg/kg
Trial: 2110954
Drug: Midazolam 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.45 mg/kg
Trial: 394555
Drug: Hyperbaric 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric 5% lidocaine with 75 mg/ml glucose concentration
Trial: 394555
Drug: Hyperbaric 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric 5% lidocaine with 50 mg/ml glucose concentration
Trial: 394555
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of both hyperbaric 5% lidocaine solutions
Trial: 30421023
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of imatinib therapy
Trial: 30421023
Drug: Dasatinib treatment
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib treatment after molecular recurrence
Trial: 30421023
Drug: Time from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time from diagnosis to discontinuation of imatinib therapy
Trial: 30421023
Drug: Duration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duration of imatinib therapy
Trial: 22282101
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg estradiol
Trial: 22282101
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg estradiol
Trial: 22282101
Drug: 0.375 mg
RxNorm normalized name: vitamin A 0.375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375 mg estradiol
Trial: 22282101
Drug: 0.27 mg
RxNorm normalized name: capsaicin 0.27 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.27 mg estradiol
Trial: 21050549
Drug: Control (Traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Traditional Chinese medicine or/and progesterone)
Trial: 15703502
Drug: Atorvastatin 10-20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10-20 mg
Trial: 15703502
Drug: Pravastatin 20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20-40 mg
Trial: 15703502
Drug: Branded simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Branded simvastatin 10-80 mg
Trial: 15703502
Drug: Generic simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Generic simvastatin 40-80 mg
Trial: 12213159
Drug: Daunorubicin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daunorubicin (5 microg) intravitreal injection
Trial: 7608243
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine (30 mg intravenously every six hours for four doses)
Trial: 7608243
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline solution, intravenously every six hours for four doses)
Trial: 1695308
Drug: Isradipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (mean dose of 3.6 mg daily)
Trial: 1695308
Drug: Nifedipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (mean dose of 50 mg daily)
Trial: 30971174
Drug: N-SORB (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-SORB (1 mL, twice daily)
Trial: 25347938
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg ipragliflozin once daily for 24 weeks
Trial: 31607191
Drug: Mindfulness-based art
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based art therapy (MBAT)
Trial: 21366847
Drug: Aliskiren/HCTZ 150/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren/HCTZ 150/12.5 mg
Trial: 19197536
Drug: Oral liarozole
RxNorm normalized name: letrozole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liarozole (75 or 150 mg/day)
Trial: 16492838
Drug: Amantadine sulfate
RxNorm normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine sulfate 100 mg
Trial: 31776742
Drug: Sequential fluoroscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential fluoroscopy guidance
Trial: 30679232
Drug: HMG-CoA reductase
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG-CoA reductase inhibitor or blocking antibody against proprotein convertase subtilisin/kexin type 9
Trial: 23713297
Drug: Warm needling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm needling therapy combined with rehabilitation training
Trial: 20126902
Drug: TR+ (non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR+ (non-surgical periodontal treatment)
Trial: 20126902
Drug: TR- (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TR- (no treatment for periodontal disease)
Trial: 17003306
Drug: Pioglitazone (PIO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO group; 45 mg/day)
Trial: 7770136
Drug: Alkalinizing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinizing therapy (group I)
Trial: 7770136
Drug: L-carnitine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (group II)
Trial: 7770136
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (group III)
Trial: 31585725
Drug: Vi-DT (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vi-DT (25 µg)
Trial: 30880698
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy with lopinavir/ritonavir plus lamivudine (DT group)
Trial: 30880698
Drug: Chinese first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese first-line triple-therapy regimen (TT group)
Trial: 28882910
Drug: Locally produced
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Locally produced lipid-based nutrient supplement (LNS)
Trial: 26882609
Drug: Common treatment
RxNorm normalized name: Common carp
DrugBank: Common carp (DB10614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Common treatment group
Trial: 20861583
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) 30-70 mg/day
Trial: 19032135
Drug: Ciprofloxacin otic
RxNorm normalized name: ciprofloxacin otic
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin otic solution 0.2% (twice daily for 7 days)
Trial: 19032135
Drug: Polymyxin B-neomycin-hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (3 times daily for 7 days)
Trial: 19032135
Drug: Ciprofloxacin otic
RxNorm normalized name: ciprofloxacin otic
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin otic solution 0.2% (for patients with P. aeruginosa)
Trial: 19032135
Drug: Polymyxin B-neomycin-hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (for patients with P. aeruginosa)
Trial: 19032135
Drug: Ciprofloxacin otic
RxNorm normalized name: ciprofloxacin otic
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin otic solution 0.2% (for patients with S. aureus)
Trial: 19032135
Drug: Polymyxin B-neomycin-hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymyxin B-neomycin-hydrocortisone (PNH) otic solution (for patients with S. aureus)
Trial: 383274
Drug: 1-phenylalanine mustard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-phenylalanine mustard (L-PAM)
Trial: 3886395
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg plus codeine 60 mg
Trial: 24612093
Drug: 10-day hybrid
RxNorm normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 10 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Trial: 24612093
Drug: 12-day hybrid
RxNorm normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 12 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Trial: 24612093
Drug: 14-day hybrid
RxNorm normalized name: Ricinus hybridus oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day hybrid therapy (esomeprazole 40 mg, amoxicillin 1 gm twice daily for 14 days, plus clarithromycin 500 mg and metronidazole 500 mg twice daily for the final 7 days)
Trial: 19606244
Drug: 0.1 N
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 N hydrochloric acid (HCl) infusion
Trial: 17621237
Drug: Darunavir (TMC114)
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darunavir (TMC114) with low-dose ritonavir (600/100 mg twice daily)
Trial: 15590214
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated estrogen combined with 5 mg medroxyprogesterone acetate
Trial: 15590214
Drug: 50 mcg
RxNorm normalized name: D3, 50 mcg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mcg transdermal estrogen alone
Trial: 10022995
Drug: Intraperitoneal cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal cisplatin (70 mg/m2) and intravenous carboplatin (target AUCs of 4, 5, 6, and 7) with G-CSF (50 microgram/m2 from day 7 to 16)
Trial: 2647846
Drug: Perindopril (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (8 mg once daily)
Trial: 29541862
Drug: Desmopressin acetate
RxNorm normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin acetate nasal spray (0.1 mg/ml, 10 μg/spray) once daily for 10 days
Trial: 29541862
Drug: Desmopressin acetate
RxNorm normalized name: Desmopressin Acetate
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Desmopressin acetate nasal spray
Trial: 29757889
Drug: 3-signal T-cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-signal T-cell activation (T-cell receptor activation, CD137/4-1BB stimulation, interleukin-2)
Trial: 27358142
Drug: Lactulose oral
RxNorm normalized name: lactulose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose oral solution, 15 ml once a day, maintenance dose of 515 ml/time as needed, treatment lasted for six weeks.
Trial: 24768330
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate (IM) treatment alone (Arm B)
Trial: 10096462
Drug: Add-back hormone
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add-back hormone replacement therapy (HRT)
Trial: 10096462
Drug: High-dose progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose progestogen
Trial: 10096462
Drug: Low-dose progestogen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose progestogen plus cyclical etidronate
Trial: 10096462
Drug: Standard and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard and low-dose HRT add-back
Trial: 10096462
Drug: Low-dose and
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose and standard-dose add-back HRT
Trial: 7000239
Drug: Sauna (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sauna (twice for 25 minutes at 85 degrees C)
Trial: 29973367
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose level ≥200 mg/dL in participants with known diabetes
Trial: 30098071
Drug: Once-daily, prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily, prolonged-release tacrolimus (PR-T)
Trial: 30098071
Drug: Twice-daily, immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily, immediate-release tacrolimus (IR-T)
Trial: 15175957
Drug: Postoperative two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative two drug chemotherapy for stage I in intermediate risk or anaplasia reduced from 3 courses to 1 course